Eli Lilly has fallen behind? The new generation oral weight-loss drug Foundayo has a sluggish start, while Novo Nordisk overtakes with five times the number of prescriptions.
```
The newly launched oral weight-loss drug Foundayo by Eli Lilly saw much fewer prescriptions in its initial period compared to its competitors, causing the market to question whether it can catch up to Novo Nordisk in the oral weight-loss drug sector.
According to RBC Capital Markets analyst Trung Huynh, citing